| Literature DB >> 29289937 |
Ditte Beck Jepsen1,2, Katja Thomsen2,3, Stinus Hansen2,4, Niklas Rye Jørgensen5,6, Tahir Masud1,2,7, Jesper Ryg1,2.
Abstract
OBJECTIVE: To investigate the effect of whole-body vibration exercise (WBV) on fracture risk in adults ≥50 years of age.Entities:
Keywords: accidental falls; exercise; fractures; meta-analysis; wbv; whole-body vibration
Mesh:
Year: 2017 PMID: 29289937 PMCID: PMC6027066 DOI: 10.1136/bmjopen-2017-018342
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram presenting the literature searches and the included studies.
Description of the included studies
| Author, year (reference) | Design | Setting | Participants | Women | Age | Analysed | Outcomes | Supervision | Adherence |
| Beck and Norling, 2010 | Three-arm RCT | Australian independently living postmenopausal women | 47 | 100 | 71.5±9.5 | ITT/PP | aBMD hip and spine, BUA of calcaneus, falls as adverse effects | Yes | 92.1% LWBV, 91% HWBV |
| Buckinx | Two-arm RCT | Belgium nursing home residents | 62 | 76 | 83.2±7.9 | ITT | Falls | Yes | 91.9% |
| Corrie | Three-arm RCT vWBV versus svWBV versus sham | England referred to Geriatric falls clinic | 61 | 61 | 80.2±6.5 | ITT | Turnover markers (CTX, P1NP) | Yes | 77% vWBV |
| Gomez-Cabello | Two-arm RCT | Spain non-institutionalised elderly | 49 | 59 | WBV 75.2±4.7 | ITT | aBMD hip and spine, pQCT | Yes | Average 90.15%±10.73% |
| Iwamoto | Two-arm RCT | Japan osteoporotic women | 50 | 100 | 55–88 | Not stated | aBMD spine, falls as adverse effects | Not stated | Not stated |
| Kiel | Two-arm RCT | North America independently living elderly | 174 | 67 | 82±7 | ITT | vBMD hip and spine, turnover markers (CTX, P1NP) | Electronic monitoring | 68% WBV 79% placebo |
| Leung | Two-arm cluster RCT | China | 710 | 100 | 74.5±7.1 | ITT | Fractures, falls, aBMD hip and spine | Electronic monitoring | 66% WBV |
| Liphardt | Two-arm RCT | Canadaosteopenic women | 42 | 100 | 58.5±3.3 | Not stated | HRpQCT, aBMD | Yes | 90% |
| Santin-Medeiros | Two-arm RCT | Spain women >79 years | 43 | 100 | 82.4±5.7 | ITT/PP | aBMD hip | Yes | >80% |
| SitjÃ-Rabert | Two-arm RCT | Spain nursing home residents >65 years | 159 | 67 | 82 | ITT | Falls | Yes | >75% |
| Von Stengel | Three-arm RCT | Germany women ≥65s year, living independently | 151 | 100 | 68.5±3.1 | ITT | Falls, aBMD hip and spine | Attendance list | WBV+exercise 80%, exercise 75% home training sessions |
| Von Stengel | Three-arm RCT vWBV versus svWBV versus wellness therapy | Germany women ≥65 years, living independently | 108 | 100 | 68.5±3.1 | ITT | aBMD femoral neck and spine | Attendance logs | vWBV 73%, svWB 68%, con 71% |
| Verschueren | Three-arm RCT | Belgium postmenopausal women non-institutionalised | 70 | 100 | 58–74 | Not stated | aBMD hip and spine, turnover markers (CTX) | Not stated | Not stated |
| Verschueren | Four-arm RCT | Belgium women living in nursing homes | 113 | 100 | 79.6 | ITT | aBMD hip | Yes | >90% |
aBMD, areal bone mineral density; BUA, calcaneal quantitative ultrasound; CON, controls; CTX, carboxy terminal collagen crosslink; Dvit, conventional dose vitamin D; HDvit, high-dose vitamin D; HRpQCT, high-resolution peripheral quantitative CT, HWBV, high-magnitude whole-body vibration; ITT, intent to treat; LWBV, low-magnitude whole-body vibration; P1NP, amino terminal propeptide of type I collagen; PP, per protocol; pQCT, peripheral quantitative CT; svWBV, side-alternating whole-body vibration; RCT, randomised controlled trials; vBMD, volumetric bone mineral density; vWBV, vertical whole-body vibration; WBV, whole-body vibration exercise.
Intervention parameters in the included studies
| Author | Intervention (frequency, peak-to-peak displacement/amplitude, peak acceleration) | Vibration type/device | Protocol exercise | Training time (total vibration per session, training frequency) | Duration | Footwear |
| Beck and Norling | LWBV 30 Hz, not stated, 0.3 | vWBV/ | Standing full upright no bending knees slightly bent | 15 min, | 8 months | Not stated |
| Beaudart | 30 Hz | vWBV/ | Standing on two feet knees flexed | 75 s, | 6 months | Shoeless |
| Corrie | vWBV 28.4 Hz, 1.3 mm peak to peak, 1.5 | vWBV/ | Standing with bent knees | 6 min, | 12 weeks | Shoeless |
| Gomez-Cabello | 40 Hz, 2 mm amplitude, not stated | vWBV/ | Standing with knees slightly bent holding the handrail | 7.5 min, | 11 weeks | Not stated |
| Iwamoto | 20 Hz, 0.7–4.2 mm peak to peak, not stated | svWBV/ | Standing with bent knees | 4 min, | 12 months | Not stated |
| Kiel | 37 Hz, 0.09 mm amplitude, 0.3 | vWBV/not stated | Upright relaxed stand | 10 min, | 24 months | Not stated |
| Leung | 35 Hz, peak to peak<0.1 mm, 0.3 | vWBV/not stated | Upright no without bending knees | 20 min, | 18 months | Not stated |
| Liphardt | 20 Hz, 3–4 mm amplitude, not stated | svWBV/ | Stable position 30° knee flexion angel | 10 min, | 12 months | Not stated |
| Santin-Medeiros | 20 Hz, 2 mm amplitude, not stated | vWBV/ | 18 different exercises, squats | 6–6.5 min, | 8 months | Not stated |
| SitjÃ-Rabert | 30–35 Hz, 2–4 mm amplitude, not stated | vWBV/ | 30 min static/dynamic exercises | 3–6 min, | 6 weeks | Not stated |
| Von Stengel | 25–35 Hz, 1.7 mm amplitude, not stated | vWBV/ | 45 min dancing, balance and gymnastics and 15 min dynamic leg strengthening with WBV and two at home sessions (20 min) with no vibration | 6 min, | 18 months | Not stated |
| Von Stengel | vvWBV, 35 Hz, 1.7 mm peak to peak, 8 | vWBV/ | Standing position, seven, one or two-legged dynamic leg strengthening exercises | 10 min, | 18 months | Flat-soled shoes |
| Verschueren | 35–40 Hz, 1.7–2.5 mm amplitude, 2.28–5.09 | vWBV/ | Static and dynamic exercises on the vibration platform | 20 min, | 6 months | Gymnastic shoes |
| Verschueren | 30–40 Hz, not stated, 1.6–2.2 | vWBV/ | Static and dynamic exercises on the vibration platform | 12 min, | 6 months | Not stated |
g=9.81 m/s2.
HWBV, high-magnitude vibration; LWBV, ow-magnitude vibration; svWBV, side-alternating whole-body vibration; vWBV, vertical whole-body vibration.; WBV, whole body vibration.
Figure 2The risk of bias assessment.
Figure 3Effect of WBV on the relative risk of experiencing a fracture. WBV, whole-body vibration.
Figure 4Forest plot of the effect of WBV. (A) The rate ratio of the fall rate/person-years between the WBV and control group. (B) The RR of experiencing one or more falls. Area of each square is proportional to study weight in meta-analysis and horizontal lines represent exact 95% CIs. Diamonds represent pooled effect estimates from random effects meta-analysis. RR, risk ratio; WBV, whole-body vibration.
Figure 5The effect of WBV exercise in forest plots on (A) areal BMD of the lumbar spine with weighted mean difference and 95% CI, divided in subgroups with vertical vibration and side-alternating vibration, (B) areal BMD in total hip with weighted mean difference and 95% CI, (C) volumetric BMD of the distal tibia with weighted mean difference with 95% CI and (D) WBVs effect on volumetric BMD of the distal radius with weighted mean difference and 95% CI. Area of each square is proportional to study weight in meta-analysis and horizontal lines represent exact 95% CI. Diamonds represent pooled effect estimates from random effects meta-analysis. BMD, bone mineral density; WBV, whole-body vibration.
Figure 6Presents the effect of WBV exercise on bone resorption markers in forest plot with CTX and the reported effect on bone formation marker amino terminal P1NP. Area of each square is proportional to study weight in meta-analysis and horizontal lines represent exact 95% CIs. Diamonds represent pooled effect estimates from random effects meta-analysis. CTX, carboxy-terminal collagen cross-link; P1NP, propeptide of type I collagen; WBV, whole-body vibration.
Summary of findings table presents the findings and the quality of each outcome using the GRADE considerations
| WBV compared with usual care for fracture risk | |||||
| Bibliography | |||||
| Outcomes | No of participants | Quality of the evidence | Relative effect | Anticipated absolute effects | |
| Risk with usual care | Risk difference with WBV | ||||
| Fractures | 710 | ⨁⨁⨁◯ | RR 0.48 | 2 per 100 | 1 fewer per 100 |
| Fall rate/person-years | 746 | ⨁⨁⨁◯ | Rate ratio 0.67 | 34 per 100 | 11 fewer per 100 |
| The risk of experiencing falls (fallers) | 805 | ⨁⨁◯◯ | RR 0.76 | 23 per 100 | 6 fewer per 100 |
| Total bone mineral density lumbar spine (BMD spine) | 911 | ⨁⨁⨁◯ | – | Mean 0 | |
| BMD total hip (BMD hip) | 870 | ⨁⨁◯◯ | – | Mean 0 | |
| Volumetric bone mineral density tibia | 80 | ⨁⨁◯◯ | – | Mean 0.68 lower | |
| Volumetric BMD radius | 80 | ⨁◯◯◯ | – | Mean 1.87 higher | |
| Serum biomarker of bone resorption (CTX) | 138 | ⨁⨁◯◯ | – | Mean 0.01 higher | |
| Serum biomarker of bone formation (P1NP) | 118 | ⨁⨁◯◯ | – | Mean 4.92 higher | |
The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
High quality: We are very confident that the true effect lies close to that of the estimate of the effect; Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
*Serious imprecision, due to the 95% CI around the estimate of effect includes both the possibility of no effect and appreciable benefit.
†Serious study limitations—lack of blinding of the participants reporting falls.
‡Serious study limitations—lack of blinding of the participants reporting fall, and serious imprecision, due to the 95% CI around the pooled estimate of effect includes both the possibility of no effect and appreciable benefit.
§Indirectness (surrogate marker for bone strength).
¶Indirectness, and statistical heterogeneity
**Indirectness, and imprecision due to the 95% CI around the estimate of effect includes both the possibility of no effect and appreciable benefit.
††indirectness, and imprecision due to the 95% CI around the estimate of effect includes both the possibility of no effect and appreciable benefit and statistical heterogeneity.
BMD, bone mineral density; CTX, carboxy-terminal collagen cross-link; GRADE, Working Group grades of evidence; P1NP, propeptide of type I collagen; RCTs, randomised controlled trials; RR, risk ratio; WBV, whole-body vibration.